title: Estimating quality of life in acute venous thrombosis.
abstract: OBJECTIVE
  Future funding for new treatments in venous thromboembolism will be guided by cost-utility analyses. There is little available information on the utility of acute venous thromboembolism, limiting the validity of economic analyses.
  
  
  OBJECTIVE
  To measure the quality of life in the health states relating to thromboembolism cost-utility analyses.
  
  
  METHODS
  A prospective cohort study.
  
  
  METHODS
  A single-center, university-affiliated thrombosis clinic.
  
  
  METHODS
  Two hundred sixteen thrombosis clinic patients with a history of lower limb deep vein thrombosis (DVT) or pulmonary embolism (PE).
  
  
  METHODS
  Participants consented to take a standard gamble interview. Each participant rated the quality of life in acute DVT, acute PE, and bleeding complication health states.
  
  
  METHODS
  The standard gamble measured quality of life (utility value) for acute DVT, acute PE, major intracranial bleeding event, minor intracranial bleeding event, and gastrointestinal bleeding event.
  
  
  RESULTS
  Two hundred fifteen responses were included in the analysis. Twenty-six percent had experienced both PE and DVT; 54%, DVT alone; and 20%, PE alone. Forty-two percent had experienced more than 1 episode of thrombosis, and 23% had had cancer-associated thrombosis. We found the median utility for acute DVT was 0.81 (interquartile range [IQR], 0.55-0.94); acute PE, 0.75 (IQR, 0.45-0.91); major intracranial bleeding event, 0.15 (IQR, 0.00-0.65); minor intracranial bleeding event, 0.75 (IQR, 0.55-0.92); and gastrointestinal bleeding event, 0.65 (IQR, 0.15-0.86). The median length of symptoms for DVT or PE was 1 week (IQR, <1-3 weeks).
  
  
  CONCLUSIONS
  To our knowledge, this is the largest published study on utilities in which the participants had personal experience of venous thromboembolism. We present unique information for economic analyses but have also identified future challenges for research in this area. Our summary results differ from those previously published, and we found wide variation in individual responses.
authors.affiliation: Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Kerstin
authors.initials: K
authors.lastname: Hogg
authors.forename: Miriam
authors.initials: M
authors.lastname: Kimpton
authors.forename: Marc
authors.initials: M
authors.lastname: Carrier
authors.forename: Douglas
authors.initials: D
authors.lastname: Coyle
authors.forename: Melissa
authors.initials: M
authors.lastname: Forgie
authors.forename: Philip
authors.initials: P
authors.lastname: Wells
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D015331:Cohort Studies; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D009864:Ontario; D011446:Prospective Studies; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors; D011795:Surveys and Questionnaires; D020246:Venous Thrombosis / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000209:etiology / Q000523:psychology*
chemical_list: D000925:Anticoagulants